Posts

A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.

/by

Authors: Barth Wilsey, Thomas Marcotte, Alexander Tsodikov, Jeanna Millman, Heather Bentley, et al
The Journal of Pain, June 2008
—
The Food and Drug Administration (FDA), Substance Abuse and Mental Health Services Administration (SAMHSA), and the National Institute for Drug Abuse (NIDA) report that no sound scientific studies support the medicinal use of cannabis. Despite this lack of scientific validatio…

Read more

Fitness to drive in spite (because) of THC.

/by

Authors: Peter Strohbeck-Kühner, Gisela Skopp, Rainer Mattern
Archiv für Kriminologie, July-August 2007
—
Attention-deficit/hyperactivity disorder (ADHD) is characterized by a lack of concentration and/or an altered activation level. People with ADHD are found to violate traffic regulations, to commit criminal offences and to be involved in traffic accidents more often than the st…

Read more

Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.

/by

Authors: Jonathan D. Wilkinson, Elizabeth M. Williamson
Journal of Dermatological Science, February 2007
—
BACKGROUND: Cannabinoids from cannabis (Cannabis sativa) are anti-inflammatory and have inhibitory effects on the proliferation of a number of tumorigenic cell lines, some of which are mediated via cannabinoid receptors. Cannabinoid (CB) receptors are present in human skin and…

Read more

The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.

/by

Authors: Luciano De Petrocellis, Dominique Melck, Antonella Palmisano, Tiziana Bisogno, et al
PNAS, 7 July 1998
—
Anandamide was the first brain metabolite shown to act as a ligand of “central” CB1 cannabinoid receptors. Here we report that the endogenous cannabinoid potently and selectively inhibits the proliferation of human breast cancer cells in vitro. Anandamide dose-dependently inhi…

Read more